25 April – 7 May 2022


1: Cross AJ, Thomas D, Liang J, Abramson MJ, George J, Zairina E. Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care. Cochrane Database Syst Rev. 2022 May 6;5:CD012652. doi: 10.1002/14651858.CD012652.pub2. PMID: 35514131.

2: Murgia N, Gambelunghe A. Occupational COPD-The most under-recognized occupational lung disease? Respirology. 2022 May 5. doi: 10.1111/resp.14272. Epub ahead of print. PMID: 35513770.

3: Carlson SA, Wheaton AG, Watson KB, Liu Y, Croft JB, Greenlund KJ. Geographic Differences in Sex-Specific Chronic Obstructive Pulmonary Disease Mortality Rate Trends Among Adults Aged ≥25 Years – United States, 1999-2019. MMWR Morb Mortal Wkly Rep. 2022 May 6;71(18):613-618. doi: 10.15585/mmwr.mm7118a1. PMID: 35511711.

4: Calzetta L, Ritondo BL, Zappa MC, Manzetti GM, Perduno A, Shute J, Rogliani P. The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. Eur Respir Rev. 2022 May 4;31(164):210196. doi: 10.1183/16000617.0196-2021. PMID: 35508331

5: Abraham RA, Brinker SK. Chronic Obstructive Pulmonary Disease and the Physical Examination. Med Clin North Am. 2022 May;106(3):423-435. doi: 10.1016/j.mcna.2022.02.001. Epub 2022 Apr 4. PMID: 35491063.

6: Mkorombindo T, Balkissoon R. Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease. Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):285-297. doi: 10.15326/jcopdf.2022.0318. PMID: 35487702.

7: Alisamir M, Ebrahimi M, Rahim F. Anemia in chronic obstructive pulmonary disease: A systematic review. Respir Investig. 2022 Apr 25:S2212-5345(22)00041-7. doi: 10.1016/j.resinv.2022.03.006. Epub ahead of print. PMID: 35484075.

8: Stafinski T, Nagase FI, Avdagovska M, Stickland MK, Menon D. Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review. BMC Health Serv Res. 2022 Apr 26;22(1):557. doi: 10.1186/s12913-022-07779-9. PMID: 35473597; PMCID: PMC9039605.

9: Wu B, Mannino D, Mu G, Stiegler M, Bogart M. Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. Pulm Ther. 2022 Apr 25. doi: 10.1007/s41030-022-00189-6. Epub ahead of print. PMID: 35467260.

10: The Lancet Respiratory Medicine. COPD: a complex, multifactorial, but preventable disease? Lancet Respir Med. 2022 May;10(5):421. doi: 10.1016/S2213-2600(22)00141-2. Epub 2022 Apr 13. PMID: 35429448.

11: Cho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. Lancet Respir Med. 2022 May;10(5):485-496. doi: 10.1016/S2213-2600(21)00510-5. Epub 2022 Apr 12. PMID: 35427534.

12: Agustí A, Melén E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene- environment interactions across the lifespan. Lancet Respir Med. 2022 May;10(5):512-524. doi: 10.1016/S2213-2600(21)00555-5. Epub 2022 Apr 12. PMID: 35427533.

13: Lee H, Sin DD. GETting to know the many causes and faces of COPD. Lancet Respir Med. 2022 May;10(5):426-428. doi: 10.1016/S2213-2600(22)00049-2. Epub 2022 Apr 12. PMID: 35427529.

14: MacDonald DM, Mkorombindo T, Ling SX, Adabag S, Casaburi R, Connett JE, Helgeson ES, Porszasz J, Rossiter HB, Stringer WW, Voelker H, Zhao D, Dransfield MT, Kunisaki KM. Heart Rate Variability on 10-Second Electrocardiogram and Risk of Acute Exacerbation of COPD: A Secondary Analysis of the BLOCK COPD Trial. Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):226-236. doi: 10.15326/jcopdf.2021.0264. PMID: 35403415.

15: Krishnan JK, Ancy KM, Oromendia C, Hoffman KL, Easthausen I, Leidy NK, Han MK, Bowler RP, Christenson SA, Couper DJ, Criner GJ, Curtis JL, Dransfield MT, Hansel NN, Iyer AS, Paine Iii R, Peters SP, Wedzicha JA, Woodruff PG, Ballman KV, Martinez FJ; SPIROMICS Investigators. Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument. Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):195-208. doi: 10.15326/jcopdf.2021.0263. PMID: 35403414.

16: Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, Haldar K, Wright A, Novotny P, Parker S, Glover S, Finch J, Quann N, Brookes CL, Hobson R, Ibrahim W, Russell RJ, John C, Grimbaldeston MA, Choy DF, Cheung D, Steiner M, Greening NJ, Brightling CE. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022 May;10(5):469-477. doi: 10.1016/S2213-2600(21)00556-7. Epub 2022 Mar 24. PMID: 35339234.

17: Singh D. IL-33 in COPD: the hunt for responder subgroups. Lancet Respir Med. 2022 May;10(5):425-426. doi: 10.1016/S2213-2600(22)00005-4. Epub 2022 Mar 24. PMID: 35339232.

18: Press VG, Randall K, Hanser A. Evaluation of COPD Chronic Care Management Collaborative to Reduce Emergency Department and Hospital Revisits Across U.S. Hospitals. Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):209-225. doi: 10.15326/jcopdf.2021.0273. PMID: 35322625.

19: Hesse K, Bourke S, Steer J. Heart failure in patients with COPD exacerbations: Looking below the tip of the iceberg. Respir Med. 2022 May;196:106800. doi: 10.1016/j.rmed.2022.106800. Epub 2022 Mar 2. PMID: 35306385.

20: Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 May;10(5):447-458. doi: 10.1016/S2213-2600(21)00511-7. Epub 2022 Mar 10. PMID: 35279265.

21: Sack CS, Manicone AM. Getting to the How and Why: Are Individuals with Chronic Obstructive Pulmonary Disease More Susceptible to the Health Effects of Air Pollution Exposure? Am J Respir Crit Care Med. 2022 May 1;205(9):978-980. doi: 10.1164/rccm.202202-0293ED. PMID: 35271429.

22: Bhatt SP. Rome Criteria for Exacerbation of Chronic Obstructive Pulmonary Disease: Not Built in a Day. Am J Respir Crit Care Med. 2022 May 1;205(9):1124-1125. doi: 10.1164/rccm.202110-2253LE. PMID: 35196475.

23: Ushida K, Shimizu A, Hori S, Yamamoto Y, Momosaki R. Hospital Frailty Risk Score Predicts Outcomes in Chronic Obstructive Pulmonary Disease Exacerbations. Arch Gerontol Geriatr. 2022 May-Jun;100:104658. doi: 10.1016/j.archger.2022.104658. Epub 2022 Feb 11. PMID: 35190332.

24: Bhatt SP, Blauer-Peterson C, Buysman EK, Bengtson LGS, Paine Iii SR. Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD. Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):135-153. doi: 10.15326/jcopdf.2021.0256. PMID: 35157792.

25: Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG, Ortega VE, Peters SP, Hoffman EA, Buhr RG, Dolezal BA, Tashkin DP, Liou TG, Bateman LA, Schroeder JD, Martinez FJ, Barr RG, Hansel NN, Comellas AP, Rennard SI, Arjomandi M, Paine Iii R. Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):111-121. doi: 10.15326/jcopdf.2021.0241. PMID: 35114743.

26: Wedzicha JA. Vaccines for COPD exacerbation prevention: do they work? Lancet Respir Med. 2022 May;10(5):422-423. doi: 10.1016/S2213-2600(22)00007-8. Epub 2022 Jan 10. PMID: 35026178.

27: Exarchos K, Aggelopoulou A, Oikonomou A, Biniskou T, Beli V, Antoniadou E, Kostikas K. Review of Artificial Intelligence Techniques in Chronic Obstructive Lung Disease. IEEE J Biomed Health Inform. 2022 May;26(5):2331-2338. doi: 10.1109/JBHI.2021.3135838. Epub 2022 May 5. PMID: 34914601.

28: Yu TZ, Tatum RT, Saxena A, Ahmad D, Yost CC, Maynes EJ, O’Malley TJ, Massey HT, Swol J, Whitson BA, Tchantchaleishvili V. Utilization and outcomes of extracorporeal CO<sub>2</sub> removal (ECCO<sub>2</sub> R): Systematic review and meta-analysis of arterio-venous and veno-venous ECCO<sub>2</sub> Rapproaches. Artif Organs. 2022 May;46(5):763-774. doi: 10.1111/aor.14130. Epub 2021 Dec 12. PMID: 34897748.

29: Dobric A, De Luca SN, Spencer SJ, Bozinovski S, Saling MM, McDonald CF, Vlahos R. Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease. Pharmacol Ther. 2022 May;233:108017. doi: 10.1016/j.pharmthera.2021.108017. Epub 2021 Oct 7. PMID: 34626675.

30: Nigro SC, Sobieraj DM. Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Ann Pharmacother. 2022 May;56(5):582-591. doi: 10.1177/10600280211038353. Epub 2021 Aug 12. PMID: 34382422.

31: Aldan G, Helvaci A, Ozdemir L, Satar S, Ergun P. Multidimensional factors affecting medication adherence among patients with chronic obstructive pulmonary disease. J Clin Nurs. 2022 May;31(9-10):1202-1215. doi: 10.1111/jocn.15976. Epub 2021 Jul 26. PMID: 34309101.


1: Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V. Eosinophilia induced by blocking the IL-4/IL-13 pathway. Potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022 May 6:0. doi: 10.18176/jiaci.0823. Epub ahead of print. PMID: 35522053.

2: Saglani S, Cohen RT, Chiel LE, Halayko AJ, Pascoe CD, Custovic A. Update in Asthma 2021. Am J Respir Crit Care Med. 2022 May 5. doi: 10.1164/rccm.202203-0439UP. Epub ahead of print. PMID: 35511755.

3: Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, Yancey SW. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. ERJ Open Res. 2022 May 3;8(2):00560-2021. doi: 10.1183/23120541.00560-2021. PMID: 35509441; PMCID: PMC9062111.

4: Tan HS, McAnally HM, Dummer J, Hancox RJ. Lifetime cannabis exposure and small airway function in a population-based cohort study. ERJ Open Res. 2022 May 3;8(2):00688-2021. doi: 10.1183/23120541.00688-2021. PMID: 35509440; PMCID: PMC9062301.

5: Martin M, Penque M, Wrotniak BH, Qiao H, Territo H. Single-Dose Dexamethasone Is Not Inferior to 2 Doses in Mild to Moderate Pediatric Asthma Exacerbations in the Emergency Department. Pediatr Emerg Care. 2022 May 3. doi: 10.1097/PEC.0000000000002727. Epub ahead of print. PMID: 35507383.

6: Domínguez-Ortega J, Luna-Porta JA, Olaguibel JM, Barranco E, Arismendi E, Barroso B, Betancor D, Bobolea I, Caballero ML, Cárdaba B, Cruz MJ, Curto E, González-Barcala FJ, Losantos-García I, Martínez-Rivera C, Mendez-Brea P, Mullol J, Muñoz X, Picado C, Plaza V, Del Pozo V, Rial MJ, Sastre J, Soto L, Valero A, Valverde-Monge M, Quirce S. Exacerbations among patients with asthma are largely dependent on the presence of multimorbidity. J Investig Allergol Clin Immunol. 2022 May 2:0. doi: 10.18176/jiaci.0816. Epub ahead of print. PMID: 35503227.

7: Hasan Arshad S. Does allergen Immunotherapy for allergic rhinitis prevent asthma? Ann Allergy Asthma Immunol. 2022 Apr 29:S1081-1206(22)00392-1. doi: 10.1016/j.anai.2022.04.028. Epub ahead of print. PMID: 35500864.

8: Matucci A, Nencini F, Maggiore G, Chiccoli F, Accinno M, Vivarelli E, Bruno C, Locatello LG, Palomba A, Nucci E, Mecheri V, Perlato M, Rossi O, Parronchi P, Maggi E, Gallo O, Vultaggio A. High proportion of inflammatory CD62L<sup>low</sup> eosinophils in blood and nasal polyps of severe asthma patients. Clin Exp Allergy. 2022 May 1. doi: 10.1111/cea.14153. Epub ahead of print. PMID: 35490414.

9: Yamane M, Ohnishi H, Tsuji K, Anabuki K, Yokoyama A. Dupilumab-induced peripheral neuropathy in a patient with severe asthma. Ann Allergy Asthma Immunol. 2022 May;128(5):611. doi: 10.1016/j.anai.2022.01.028. PMID: 35489800.

10: Rabe KF, Pavord ID, Castro M, Wechsler ME, Daizadeh N, Kapoor U, Ortiz B, Radwan A, Johnson RR, Rowe PJ, Deniz Y, Jacob-Nara JA. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL<sup>-1</sup>. Eur Respir J. 2022 Apr 29:2102577. doi: 10.1183/13993003.02577-2021. Epub ahead of print. PMID: 35487538.

11: van Meel ER, Mensink-Bout SM, den Dekker HT, Ahluwalia TS, Annesi-Maesano I, Arshad SH, Baïz N, Barros H, von Berg A, Bisgaard H, Bønnelykke K, Carlsson CJ, Casas M, Chatzi L, Chevrier C, Dalmeijer G, Dezateux C, Duchen K, Eggesbø M, van der Ent C, Fantini M, Flexeder C, Frey U, Forastiere F, Gehring U, Gori D, Granell R, Griffiths LJ, Inskip H, Jerzynska J, Karvonen AM, Keil T, Kelleher C, Kogevinas M, Koppen G, Kuehni CE, Lambrechts N, Lau S, Lehmann I, Ludvigsson J, Magnus MC, Mélen E, Mehegan J, Mommers M, Andersen AN, Nystad W, Pedersen ESL, Pekkanen J, Peltola V, Pike KC, de Moira AP, Pizzi C, Polanska K, Popovic M, Porta D, Roberts G, Santos AC, Schultz ES, Standl M, Sunyer J, Thijs C, Toivonen L, Uphoff E, Usemann J, Vafeidi M, Wright J, de Jongste JC, Jaddoe VWV, Duijts L. Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children. Eur Respir J. 2022 Apr 29:2102395. doi: 10.1183/13993003.02395-2021. Epub ahead of print. PMID: 35487537.

12: Niessen NM, Fricker M, McDonald VM, Gibson PG. T2-low: What do we know? – Past, present, and future of biologic therapies in non-eosinophilic asthma. Ann Allergy Asthma Immunol. 2022 Apr 26:S1081-1206(22)00342-8. doi: 10.1016/j.anai.2022.04.020. Epub ahead of print. PMID: 35487388.

13: Hashimoto S, Kroes JA, Eger K, Mau-Asam P, Hofstee HB, Bendien SA, Braunstahl GJ, Broeders ME, Imming LM, Langeveld B, Maitland-van der Zee AH, Oud KT, Patberg KW, Smeenk FW, Petronella Romme EA, van Bezouw MJ, van de Ven MJ, van Veen A, van Velzen E, van Veen IH, Weersink EJ, Ten Brinke A, Sont JK, Bel EH; RAPSODI team. Real-World Effectiveness of Reslizumab in Patients with Severe Eosinophilic Asthma – “First Initiators” and “Switchers”. J Allergy Clin Immunol Pract. 2022 Apr 26:S2213-2198(22)00362-2. doi: 10.1016/j.jaip.2022.04.014. Epub ahead of print. PMID: 35487369.

14: Cazzola M, Rogliani P, Ora J, Calzetta L, Matera MG. Asthma and comorbidities: recent advances. Pol Arch Intern Med. 2022 Apr 28;132(4):16250. doi: 10.20452/pamw.16250. Epub 2022 Apr 28. PMID: 35485651.

15: Moitra S, Carsin AE, Abramson MJ, Accordini S, Amaral AFS, Anto J, Bono R, Casas Ruiz L, Cerveri I, Chatzi L, Demoly P, Dorado-Arenas S, Forsberg B, Gilliland F, Gislason T, Gullón JA, Heinrich J, Holm M, Janson C, Jogi R, Gómez Real F, Jarvis D, Leynaert B, Nowak D, Probst-Hensch N, Sánchez-Ramos JL, Raherison-Semjen C, Siroux V, Guerra S, Kogevinas M, Garcia-Aymerich J. Long-term effect of asthma on the development of obesity among adults: an international cohort study, ECRHS. Thorax. 2022 Apr 27:thoraxjnl-2021-217867. doi: 10.1136/thoraxjnl-2021-217867. Epub ahead of print. PMID: 35477559.

16: Verschakelen JA. Quantitative CT of the Lung to Study Asthma. Radiology. 2022 Apr 26:213091. doi: 10.1148/radiol.213091. Epub ahead of print. PMID: 35471116.

17: Trivedi AP, Hall C, Goss CW, Lew D, Krings JG, McGregor MC, Samant M, Sieren JP, Li H, Schechtman KB, Schirm J, McEleney S, Peterson S, Moore WC, Bleecker ER, Meyers DA, Israel E, Washko GR, Levy BD, Leader JK, Wenzel SE, Fahy JV, Schiebler ML, Fain SB, Jarjour NN, Mauger DT, Reinhardt JM, Newell JD Jr, Hoffman EA, Castro M, Sheshadri A; NHLBI Severe Asthma Research Program (SARP). Quantitative CT Characteristics of Cluster Phenotypes in the Severe Asthma Research Program Cohorts. Radiology. 2022 Apr 26:210363. doi: 10.1148/radiol.210363. Epub ahead of print. PMID: 35471111.

18: Rind DM, McQueen RB, Herron-Smith S, Herce-Hagiwara B, Gutierrez E, Campbell JD, Fluetsch N, Pearson SD. The effectiveness and value of tezepelumab for severe asthma. J Manag Care Spec Pharm. 2022 May;28(5):577-580. doi: 10.18553/jmcp.2022.28.5.577. PMID: 35471071.

19: Williams DM. The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma. J Manag Care Spec Pharm. 2022 May;28(5):581-583. doi: 10.18553/jmcp.2022.28.5.581. PMID: 35471066.

20: Ali H, Brooks C, Tzeng YC, Crane J, Beasley R, Gibson P, Pattemore P, Stanley T, Pearce N, Douwes J. Heart rate variability as a marker of autonomic nervous system activity in young people with eosinophilic and non-eosinophilic asthma. J Asthma. 2022 May 5:1-9. doi: 10.1080/02770903.2022.2070763. Epub ahead of print. PMID: 35468039.

21: Torchio R, Gobbi A, Gulotta C, Antonelli A, Dellacà R, Pellegrino GM, Pellegrino R, Brusasco V. Role of hyperpnea in the relaxant effect of inspired CO<sub>2</sub> on methacholine-induced bronchoconstriction. J Appl Physiol (1985). 2022 May 1;132(5):1137-1144. doi: 10.1152/japplphysiol.00763.2021. Epub 2022 Mar 31. PMID: 35358399.

22: Korn S, Milger K, Skowasch D, Timmermann H, Taube C, Idzko M, Voß HW, Holtdirk A, Hamelmann E, Buhl R. Corrigendum to “The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control” [Respir. Med. 195 (2022) 106793]. Respir Med. 2022 May;196:106827. doi: 10.1016/j.rmed.2022.106827. Epub 2022 Mar 26. Erratum for: Respir Med. 2022 Feb26;195:106793. PMID: 35349956.

23: Barber CM, Cullinan P, Feary J, Fishwick D, Hoyle J, Mainman H, Walters GI. British Thoracic Society Clinical Statement on occupational asthma. Thorax. 2022 May;77(5):433-442. doi: 10.1136/thoraxjnl-2021-218597. Epub 2022 Mar 21. PMID: 35314486.

24: Niewodowski D, Langton D. Learning curve for bronchial thermoplasty. Respirology. 2022 May;27(5):366-369. doi: 10.1111/resp.14248. Epub 2022 Mar 16. PMID: 35293074.

25: Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14. PMID: 35287231.

26: Singh D, Garcia G, Maneechotesuwan K, Daley-Yates P, Irusen E, Aggarwal B, Boucot I, Berend N. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Adv Ther. 2022 May;39(5):1895-1914. doi: 10.1007/s12325-022-02092-7. Epub 2022 Mar 14. PMID: 35284999.

27: Svenningsen S, Nair P. Persistent Airway Plugs: A Call for Clinical Recognition and Novel Therapies. Am J Respir Crit Care Med. 2022 May 1;205(9):977-978. doi: 10.1164/rccm.202201-0147ED. PMID: 35259080.

28: McBride SC, McCarty K, Wong J, Baskin M, Currier D, Chiang VW. A pediatric hospital-wide asthma severity score: Reliability and effectiveness. Pediatr Pulmonol. 2022 May;57(5):1223-1228. doi: 10.1002/ppul.25861. Epub 2022 Mar 28. PMID: 35182050.

29: Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. Clin Exp Allergy. 2022 May;52(5):616-627. doi: 10.1111/cea.14112. Epub 2022 Mar 9. PMID: 35174566.

30: Tang M, Elicker BM, Henry T, Gierada DS, Schiebler ML, Huang BK, Peters MC, Castro M, Hoffman EA, Fain SB, Ash SY, Choi J, Hall C, Phillips BR, Mauger DT, Denlinger LC, Jarjour NN, Israel E, Phipatanakul W, Levy BD, Wenzel SE, Bleecker ER, Woodruff PG, Fahy JV, Dunican EM. Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time. Am J Respir Crit Care Med. 2022 May 1;205(9):1036-1045. doi: 10.1164/rccm.202110-2265OC. PMID: 35104436.

31: Stout S, Murphy H, Pandya A, Yeh HW, Portnoy J. The effect of coronavirus disease 2019 on asthma visits. Ann Allergy Asthma Immunol. 2022 May;128(5):594-595. doi: 10.1016/j.anai.2022.01.027. Epub 2022 Jan 31. PMID: 35101645; PMCID: PMC8801266.

32: Geng B, Dixon AE, Ko J, Janampally P, Haselkorn T, Holweg CTJ, Casale TB, Jarjour N. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2022 May;128(5):553-560. doi: 10.1016/j.anai.2022.01.025. Epub 2022 Jan 31. PMID: 35101644.

33: Wei Y, Qiu X, Sabath MB, Yazdi MD, Yin K, Li L, Peralta AA, Wang C, Koutrakis P, Zanobetti A, Dominici F, Schwartz JD. Air Pollutants and Asthma

Pubblicato in Libra Journal Club.